This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease

This study has been completed.
Information provided by:
Cedars-Sinai Medical Center Identifier:
First received: January 23, 2009
Last updated: January 26, 2009
Last verified: January 2009

Patients with inflammatory bowel disease (IBD) will be assessed for immunologic response to pneumococcal vaccination. Patients with IBD meet criteria as outlined by the Centers for Disease Control (CDC) for pneumococcal vaccination, yet the investigators have found that pneumococcal vaccination in this population is under-utilized. It is unknown whether or not IBD or IBD-related medications impact the immune response to this recommended vaccine.

Three groups of 25 patients each will be recruited. The first group will consist of outpatients with IBD who are receiving infliximab (Remicade TM) while on concommitant immunosuppressive therapy (with either 6MP, azathioprine, or methotrexate). This group is intended to represent a common 'heavily immunosuppressed' patient group with IBD.

The second group will consist of patients with IBD seen in our outpatient clinic who are not on any immune-suppressive medications. These patients meet CDC criteria for vaccination by virtue of having a chronic medical illness. The third group will consist of healthy age-matched (to the first group) controls.

After obtaining informed consent, patients will be screened with baseline lab tests including testing for antibodies against pneumococcus. At the baseline visit, patients will also undergo a brief medical history, physical examination, and assessment of their IBD disease activity.

Included patients will then undergo a one-time intramuscular vaccination with 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM). One month later, subjects will return for a blood draw to assess for response to pneumococcal vaccination.

Condition Intervention
Inflammatory Bowel Disease Crohn Disease Ulcerative Colitis Biological: 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease

Resource links provided by NLM:

Further study details as provided by Cedars-Sinai Medical Center:

Primary Outcome Measures:
  • Response, defined by postvaccination antibody titers [ Time Frame: 1 month ]

Enrollment: 69
Study Start Date: May 2005
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
IBD, on both an anti-TNF agent and an immunomodulator
Biological: 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)
0.5mL intramuscular, one time
Other Name: Pneumovax
Experimental: 2
IBD, not on any immunosuppressive medications
Biological: 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)
0.5mL intramuscular, one time
Other Name: Pneumovax
Active Comparator: 3
Healthy, non-IBD, not on immunosuppressive medications (control arm)
Biological: 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)
0.5mL intramuscular, one time
Other Name: Pneumovax


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Males and females over the age of 18 with inflammatory bowel disease; healthy controls will be age- and sex-matched.
  2. The patient must understand and voluntarily sign and informed consent document
  3. A history of chronic (greater than 1 month) ulcerative colitis or Crohn's disease diagnosed and documented by the standard clinical, radiographic, endoscopic, and histopathologic criteria
  4. (Group 1): Outpatients at CSMC IBD center with IBD who are on maintenance anti-TNF therapy with infliximab OR ADALIMUMAB plus concomitant immunomodulator therapy (with either 6MP, AZA, or MTX)
  5. (Group 2): Outpatients at CSMC's IBD Center with documented IBD who are not on any immune-suppressive medications. Treatment with oral or topical 5-ASA products, antibiotics, or probiotics, are permitted.
  6. (Group 3): Healthy volunteers without chronic illness, not on immune-suppressive medications.

Exclusion Criteria:

  1. Hypersensitivity to any component of the vaccine
  2. Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine (including thyroid), pulmonary, cardiac, infectious, neurologic or cerebral disease. Included are ongoing chronic active conditions such as chronic active hepatitis.
  3. Patients who in the judgment of the investigator are unwilling or unable to comply with all the protocol-related assessments and procedures.
  4. History of alcohol or other drug abuse within one year, or any conditions associated with poor compliance.
  5. Patients in whom venipunctures are not feasible due to poor tolerability or lack of easy access.
  6. Healthy volunteers or patients with a history of prior pneumococcal vaccination
  7. Any condition which, in the opinion of the Investigator, places the patient at unacceptable risk if he/she were to participate in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00829595

United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
Sponsors and Collaborators
Cedars-Sinai Medical Center
Principal Investigator: Eric A Vasiliauskas, MD Cedars-Sinai Medical Center
  More Information

Responsible Party: Gil Melmed, MD, Cedars-Sinai Medical Center Identifier: NCT00829595     History of Changes
Other Study ID Numbers: 6355
Study First Received: January 23, 2009
Last Updated: January 26, 2009

Keywords provided by Cedars-Sinai Medical Center:
inflammatory bowel disease
Crohn disease
ulcerative colitis
anti tumor necrosis alpha
pneumococcal vaccine

Additional relevant MeSH terms:
Crohn Disease
Colitis, Ulcerative
Intestinal Diseases
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Pathologic Processes
Heptavalent Pneumococcal Conjugate Vaccine
Immunologic Factors
Physiological Effects of Drugs processed this record on September 21, 2017